



TRENDS-in-MEDICINE

BULLETIN:

TRANSCATHETER CARDIOVASCULAR THERAPEUTICS (TCT) – PREVIEW

September 20, 2017
by Lynne Peterson

There will be 16 late-breaker trials presented at the TCT meeting, sponsored by the Cardiovascular Research Foundation (CRF), in Denver from October 29 – November 2, 2017, along with 12 first report investigations. The ones of particular interest include:

Monday, October 30

- **ORBUSNEICH's Combo** – The results of the 572-patient HARMONEE Japanese/U.S. trial of this sirolimus-eluting metallic coronary stent with a biodegradable CD34+ polymer vs. an everolimus-eluting stent. This is a pivotal trial for Japan and a pilot study for the U.S. – 12:15 pm.
- **B. BRAUN MEDICAL's SeQuent** – The results of the DARE trial comparing this paclitaxel-eluting balloon vs. a drug-eluting stent (Abbott's Xience, which elutes everolimus) in patients undergoing percutaneous coronary intervention (PCI) for in-stent restenosis – 12:30 pm.
- **NIPRO's Filtrap** – The results of the VAMPIRE-3 trial of this distal filter protection device during PCI – 12:45 pm.

Tuesday, October 31

- **ABBOTT'S ABSORB BVS** – Even though the company discontinued sales of this bioresorbable stent, the results should be interesting from:
 - ABSORB-II 4-year outcomes – 12 N
 - ABSORB-III 3-year outcomes – 11 am
 - ABSORB-IV 30-day outcomes – 11:15 am
- **EDWARDS LIFESCIENCES' Sapien 3** – A cost-effectiveness analysis of this transcatheter aortic valve replacement (TAVR) in intermediate-risk patients – 11:40 am.
- **MEDIS and PULSE MEDICAL IMAGING TECHNOLOGY (Shanghai)'s quantitative flow ratio (QFR)** – A comparison study of this alternative to fractional flow reserve (FFR) for coronary angiography from the FAVOR-II China and FAVOR-II Europe/Japan studies – 12:45 pm.

Wednesday, November 1

- **BOSTON SCIENTIFIC's Synergy** – The results of the SENIOR trial comparing this metallic drug-eluting stent (DES) with a bioabsorbable polymer vs. a bare metal stent (BMS) with a short course of dual antiplatelet therapy (DAPT) in coronary artery disease patients age >75 – 11 am.

Trends-in-Medicine ■ 2731 N.E. Pinecrest Lakes Blvd ■ Jensen Beach FL 34957
772-285-0801 ■ Fax 772-334-0856 ■ www.trends-in-medicine.com

Trends-in-Medicine has no financial connections with any pharmaceutical or medical device company. The information and opinions expressed have been compiled or arrived at from sources believed to be reliable and in good faith, but no liability is assumed for information contained in this newsletter. Copyright ©2017.

This document may not be reproduced without written permission of the publisher.

- **ORBUSNEICH's Combo** – The results of the REDUCE trial examining 3-month vs. 12-month DAPT with this metallic stent with a biodegradable CD34+ polymer – 11:40 am.
- **Mitral valves** – The results of a series of mitral valve (MV) trials will be presenting, including:
 - **EDWARDS LIFESCIENCES' Sapien XT** – 30-day outcomes in severe mitral valve disease in patients with annular calcification or failed annuloplasty rings – 12 N.
 - **TENDYNE's mitral valve** – 1-year outcomes with this transcatheter MV replacement in patients with severe mitral regurgitation – 12:27 pm.
 - **HARPOON MEDICAL's TSD-5** – The results of the CE Mark trial with this mitral repair system – 12:39 pm.
 - **MVRX's Arto** – 6-month results with this transcatheter mitral repair device – 12:51 pm.

Thursday, November 2

- **BOSTON SCIENTIFIC's Watchman** – 5-year results with this left atrial appendage closure device vs. medical therapy in patients with non-valvular atrial fibrillation – 9:30 am.
- ***Are stents better than medical management for patients with stable ischemic heart disease?*** The first sham-controlled study, the 200-patient ORBITA trial in the U.K., may answer this question – or raise questions – 9:50 am.
- **ABBOTT/ST. JUDE MEDICAL's PressureWire** – 3-year results of the FAME-2 trial of FFR – 10:10 am.
- **Transcatheter tricuspid trials:**
 - **EDWARDS LIFESCIENCES/VALTECH CARDIO's Cardioband** – 30-day outcomes in the TRI-REPAIR trial with this tricuspid repair device – 10:30 am.
 - **EDWARDS LIFESCIENCES' Forma** – 30-days outcomes of this tricuspid repair system – 10:45 am.

